150
Participants
Start Date
April 30, 2009
Primary Completion Date
October 31, 2010
Study Completion Date
March 31, 2011
Placebo in primary cardiovascular prevention (PP)
"12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
Placebo in secondary prevention
"12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
Grape extract in primary prevention (PP)
"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
Grape extract in SP
"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
Resveratrol-enriched grape extract in PP
"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
Resveratrol-enriched grape extract in SP
"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
University Hospital Morales Meseguer, Murcia
Lead Sponsor
Hospital General Universitario Morales Meseguer
OTHER
National Research Council, Spain
OTHER_GOV